More than 1,800 employees at the Bern facility develop and manufacture innovative biotherapies derived from human plasma.
R&D Switzerland at a glance: We are strengthening our local R&D network to contribute to our global strategic goals.
We are proud to work in the field of rare and serious diseases and to provide therapy in many areas of treatment.
We also aim to make sure that nothing holds you back from getting the therapies you need.
We operate as one integrated global R&D organization that assembles coordinated global project teams.
CSL supports Investigator-Initiated Studies (IIS) that advance medical and scientific knowledge of CSL Behring products and the diseases they treat.
Every day at CSL Behring, we work as if someone's life depends on it, because it does.
CSL Behring biotherapies are manufactured in state-of-the-art facilities under stringent, controlled conditions.
At CSL, Diversity, Equity, and Inclusion (DEI) is at the core of our mission and who we are. It fuels our innovation day in and day out.
Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!
Popular search terms:
News from CSL Behring
CSL Behring welcomes members of the canton and the Executive Council.
On 28 February, the Burgerspital Bern lit up in the colours of Rare Disease Day.
Swissmedic Approves CSL Behring’s ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (H…
Bern lights up for Rare Disease Day
Listen to the podcast episode from Echo der Zeit.
CSL reported net income after tax of $2.04 billion in the first half of 2025.
A collaboration with the University of St. Gallen.
Highlighting career paths and providing insights into translational research was the aim of the EU Horizon Bio2Brain Summer S…
CSL reports 15% profit growth with a full-year net profit of $2.91 billion (1,2).
Americas
Asia Pacific
Middle East
Europe
.png?h=900&w=1600&cropregion=0,0,5000,2813&hash=96615F13EC8E3F78A3D6D015ED2DD6C3)
